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Abstract
A wide range of injuries could affect the bladder and lead to eventual loss of its integrity, with the need
for replacement or repair. Augmentation ileocystoplasty is considered till now the gold standard option
for bladder replacement, despite its associated complications. Bladder tissue engineering appears as an
appealing alternative through development of biological substitutes, which could restore structural and
functional aspects of damaged tissues and organs.
Tissue engineering relies upon three essential pillars; the scaffold, the cells seeded on scaffolds and lastly
the environmental conditions, including growth factors, cytokines and extracellular matrix (ECM) which
promote angiogenesis and neurogenesis of the regenerated organs. The choice of the scaffold and the type
of cells is a crucial and fundamental step in regenerative medicine. In this review article, we demonstrated
these three crucial factors of bladder tissue engineering, with the pros and cons of each scaffold type and
cell type used.
© 2013 Pan African Urological Surgeons’ Association. Production and hosting by Elsevier B.V. 
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The bladder could be damaged or lost via wide range of injuries,
necessitating subsequent replacement or repair. Children with∗ Corresponding author. Tel.: +20 1119906518.
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wOpen access under CC BY-NC-ND license.igh-pressure low compliant bladders as a result of congenital
nomalies such as bladder exstrophy and myelomeningocele always
uccumb to augmentation cystoplasty when medical treatment fails
1].
astrointestinal segments are always used as donor tissues for aug-
entation cystoplasty. However, several deleterious complications
an occur, such as electrolytes imbalance, urolithiasis, mucus pro-
uction, and malignancy [2].
ue to the aforementioned problems associated with gastroin-
estinal segments application, investigators and researchers have
ttempted to use alternative methods, materials, and tissues for
Open access under CC BY-NC-ND license.ladder tissue engineering. In 1917, Neuhof was the first one to
eport application of a free tissue graft for bladder replacement.
e incorporated fascia to augment bladders in dogs [3]. This
as followed afterwards by a series of experiments and clinical
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rials using several other materials as free grafts, including
kin, bladder submucosa, omentum, dura, peritoneum, placenta,
eromuscular grafts, and small intestinal submucosa [4–9]. Syn-
hetic materials such as polyvinyl sponge, tetrafluoroethylene,
elatin sponge, collagen matrices, vicryl matrices, resin-
prayed paper, and silicone were also tested experimentally and
linically [10–12].
he previously mentioned trials have usually failed due to mechani-
al, structural, functional, or biocompatibility issues. Bladder tissue
annot be easily replaced due to its elasticity and urothelial perme-
bility. Subsequently, bowel tissue remained as the gold standard
ption for more than a century after it was proposed, despite associ-
ted complications. Anastomoses between sets of urological tissues
re considered the best functional alternative, but paucity of autolo-
ous urological tissues for reconstruction remains an obstacle [13].
herefore researchers were urged to seek alternative solutions as
issue engineering due to lack of an entirely satisfactory clinical
ption [1].
issue  engineering
ladder tissue engineering appears as an appealing alternative
hrough development of biological substitutes, which could restore
tructural and functional aspects of damaged tissues and organs.
t employs aspects of cell biology, transplantation, and biomedical
ngineering.
omponents  of  tissue  engineering
issue engineering relies upon three essential pillars in the organ
egeneration process:
1) The biomaterial or the scaffold.
2) The cells seeded on the surface of the biomaterial.
3) The environmental conditions, including active growth fac-
tors [vascular endothelial growth factor (VEGF), transforming
growth factor 1 (TGF1), epidermal growth factor (EGF),
transforming growth factor   (TGF), etc.], cytokines and
extracellular matrix (ECM) which promote angiogenesis and
neurogenesis of the regenerated organs.
herefore the choice of biomaterial or scaffold and the type of cells
s a crucial and fundamental step in regenerative medicine.
iomaterials  or  scaffolds
hy  do  we  use  biomaterials  in  tissue  engineering?
he biomaterial design is fundamental in the development of engi-
eered genitourinary tissues. The type of the biomaterial plays
 critical role in controlling the structure and function of the
ngineered tissue in a preplanned manner by interacting with trans-
lanted cells or host cells.
iomaterials facilitate both the localization and delivery of cells
nd/or bioactive factors to desired non-functional sites of the body.
hey can also act as a three-dimensional (3D) cytoskeleton for the
evelopment of neo-tissues of appropriate structure, and lastly they
an guide the formation of functional new tissues [14]. In some
nstances, direct injection of cell suspensions without biomaterial
atrices has been used [15,16], but it showed technical difficulty to
ontrol the localization of transplanted cells.
r
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ppropriate regulation of cell behavior (e.g. adhesion, proliferation,
igration, differentiation) by the biomaterials is crucial to promote
he genesis of functional new tissue. Cell behavior is regulated by
ultiple interactions with the microenvironment, including interac-
ions with cell-adhesion ligands [17] and with soluble growth factors
18]. These can be provided by the biomaterial itself or integrated
nto the biomaterial to control cell behavior [19].
ladder scaffolds used must be able to support the adhesion and
roliferation of specific cell types, including urothelial cells (on
he luminal side) and smooth muscle cells which surrounds the
rothelium, and it must be able to direct proper tissue development
nd differentiation in order to form a functional adaptive compliant
ladder.
o withstand forces exerted by the surrounding tissues, the bio-
aterials must provide temporary mechanical support. In the case
f bladder replacement, the biomaterial must be able to withstand
orces resulting from bladder filling and evacuation. In addition, the
iomaterial must withstand the forces exerted on it by the pelvic
usculature during the patient’s daily activities. Mechanical sup-
ort of the biomaterials should be sustained till the engineered
ladder has sufficient mechanical integrity to acquire its complete
unctionality [20].
inally, the biomaterial must have certain properties to be processed
nto different conformations. It must be molded into a tubular shape
n cases of urethral replacement, or into a hollow spherical config-
ration in cases of bladder replacement.
haracteristics  of  ideal  scaffold
he ideal scaffold should be non-toxic, have the same mechanical
roperties as the tissue of interest, and integrate biochemical, spatial
nd topographical cues in a hierarchical manner to replicate the
roperties of native tissue (adhesive cues, mass transport, surface
exture and composition)
ypes  of  biomaterials
enerally speaking, three major types of biomaterials have been
sed for engineering of genitourinary tissues [21]; these are:
a) Naturally derived materials, such as collagen and alginate.
b) Acellular tissue matrices, such as bladder submucosa (BSM)
and small-intestinal submucosa (SIS).
c) Synthetic polymers, such as polyglycolic acid (PGA), polylactic
acid (PLA) and polylactic-co-glycolic acid (PLGA).
hese types of biomaterials have been tested for biocompatibility
ssues with primary human urothelial and bladder muscle cells [22].
aturally derived materials and acellular tissue matrices have the
otential advantage of biologic recognition, while synthetic poly-
ers can be produced enormously and quickly with controlled
roperties of strength, degradation and microstructure.
aturally  derived  scaffolds.  Collagen is purified from both animal
nd human tissues, and it is considered the most abundant structural
rotein in the body. It shows minimal inflammatory and antigenic
esponses [23] and it has been approved by the Food and Drug
dministration (FDA) for many types of medical applications [24].
o be less vulnerable to the enzymatic degradation, intermolecu-
ar cross-linking is of proven efficacy. Cross-linking can be done
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by either physical (e.g. ultraviolet radiation) or chemical (e.g. glu-
taraldehyde) techniques [25]. On the other hand, alginate is utilized
as an injectable cell delivery vehicle [26] and a cell immobilization
matrix due to its gelling properties.
A new innovative technique has been adopted recently using alginate
and collagen. They are used as ‘bio-inks’ in a newly developed
bio printing technique based on inkjet technology [27,28]. These
constructed scaffold materials can be ‘printed’ into desired scaffold
configurations using a modified inkjet printer. This new modality
can be further upgraded so that a 3D construct containing a certain
precise arrangement of cells, growth factors and ECM material can
be printed [29]. Furthermore, these constructs can be implanted into
a host serving as the backbone for a new tissue or organ.
Acellular  tissue  matrices.  Acellular tissue matrices are collagen-
enriched matrices prepared by removing antigenic cellular contents,
a process known as decellularization, using different mechani-
cal and chemical processes [30,31]. The resultant ECM retains
most of the functional and structural proteins, glycosaminoglycans
(GAGs), glycoproteins, and bioactive factors [32]. The rationale
for using such a scaffold in tissue engineering is that the resul-
tant scaffold would possess the same composition, mechanical
properties and complexity as the native tissue and integrate all
these cues in a hierarchical manner, bypassing the need to engi-
neer them into an artificial scaffold. Moreover, acellular matrices
from allogeneic, cadaveric and even xenogeneic sources could
be used as most antigenic proteins are removed by the decel-
lularization [33]. To summarize, the resulting ECM shows all
the criteria of the optimum scaffold used in tissue engineering
[34].
As acellular matrices degrade over time after process of implan-
tation, they are remodeled by native ECM proteins or by ECM
synthesized by transplanted cells. In previous trials, acellular tissue
matrices have been shown to support cell ingrowth and regeneration
of several genitourinary tissues, including urethra and bladder. They
did not exhibit any immunogenic rejection [7,35].
Acellular matrices show a wider variation in composition and physi-
cal moduli (such as tensile strength, elasticity and breaking strength)
as compared to synthetic scaffolds because it is derived from ani-
mal sources. Many components of native intact bladder are found
in bladder acellular matrix (BAM), including laminin, fibronectin,
entactin, decorin, and collagens I, III, IV, V and VI [36].
BAM is considered as one of the most representative decellularized
tissues. It has been extensively utilized in bladder tissue engineer-
ing in various animal models. It induced the ingrowth of several
cell types, including urothelial cells, smooth muscle cells, endothe-
lial cells, and nerve cells. However, there were still distinguishable
poorly organized smooth muscle cells in the scaffold center in
bladders augmented with BAMs alone. Inadequate vascularization
occurring in these augmented bladder tissues predisposed to blad-
der fibrosis and eventually affected the long-term bladder function
[37].Synthetic  polymers.  These synthetic polyesters of naturally occur-
ring -hydroxy acids are widely used in regenerative medicine.
End-products of these polymers are non-toxic, and are eliminated
from the body in the form of carbon dioxide and water [38]. Owing
i
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w53
o the thermoplasticity of these polymers, they can be easily recon-
tructed into a 3D scaffold of specified microstructure, shape and
imensions [39,40].
raft failure associated with use of synthetic polymers may manifest
y recurrent urinary tract infections, calculi formation, contracture
f grafts and graft rejection [41,42]. Moreover, although these poly-
ers can be processed into complex three-dimensional structures,
hey do not contain cues promoting cell adhesion, proliferation and
ifferentiation and do not display the same elasticity as detrusor
uscle. Another major side effect of these synthetic polymers is
ack of biologic recognition, predisposing them to be attacked by
he body immune system [19].
omposite scaffolds consisting of both natural and synthetic mate-
ials have been developed and may be useful in genitourinary tissue
ngineering. In particular, these scaffolds may be useful for engi-
eering organs that are composed of layers of cells, such as the
ladder (urothelial layer surrounded by smooth muscle cells) [43].
ells
he ability to use donor tissue efficiently and to provide the right
onditions for long-term survival, differentiation and growth are
undamental steps for successful cell transplantation strategies in
ladder tissue engineering. Various cell sources have been used for
ladder regeneration. Bladder neck and trigone areas have a higher
oncentration of urothelial progenitor cells [44], being localized in
he basal region [45]. Amniotic fluid and bone marrow-derived stem
ells can also be used in an autologous manner and have the poten-
ial to differentiate into bladder muscle [46] and urothelium [47].
mbryonic stem (ES) cells also have the potential to differentiate
nto bladder tissue [48].
ypes  of  cells  used  in  tissue  engineering
ifferentiated  native  cells  from  the  organ  of  interest  (examples  are
rothelial  and  smooth  muscle  cells)
ne of the technical limitations for applying cell-based regenerative
edicine was the inherent difficulty of growing certain human cell
ypes in large quantities. Native targeted progenitor cells are found in
very organ of the body, and this led to improved culture techniques
vercoming this technical problem. These cells are tissue-specific
nipotent cells, being derived from most organs [49].
n the past, urothelial cells were cultured in vitro, but with only
imited success. Over the last two decades, several protocols and
rials have been tested with improved success rates in urothelial
rowth and expansion [50,51]. Using modified cell culture tech-
iques; it now feasible to culture an urothelial strain from a single
pecimen that initially covers a surface area of 1 cm2 to one covering
 surface area of 4202 m2 within 8 weeks [51].
ative targeted progenitor cells are already programmed to become
he cell type needed when implanted in the tissue of interest, requir-
ng no in vitro differentiation. They can also be obtained from the
pecific organ to be regenerated, expanded and used in the same
atient without rejection, in an autologous manner, obviating the
ssues of biological recognition [50–52].
ajor concerns arose when using native progenitor cells. If cells
ere expanded from a diseased organ, there may be no longer
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nough normal cells in that organ to be obtained. Lin et al. showed
hat cultured neuropathic bladder smooth muscle cells possessed
nd maintained different characteristics than normal smooth muscle
ells in vitro [53]. On the contrary, Lai et al. were able to demonstrate
hat matrices seeded with in vitro cultured neuropathic smooth mus-
le cells, and then implanted in vivo, showed the same properties as
he constructs engineered with normal cells [54].
enetically normal progenitor cells are present even in diseased tis-
ue. They are considered as reservoirs for new cell formation, being
rogrammed to give rise to normal tissue, regardless of whether they
eside in a normal or diseased environment.
tem  cells
ue to the aforementioned obstacles associated with utilizing
rothelial and smooth muscle cells, stem cells are considered to
e ideal candidates for tissue engineering.
ypes  of  stem  cells  used  in  tissue  engineering
mbryonic  stem  (ES)  cells
luripotent human stem cells are an ideal source of cells, as they can
ifferentiate into any replacement tissue in the body. One example is
S cells. These cells have two important remarkable properties: the
bility to proliferate in an undifferentiated state, but still pluripotent
self-renewal) and the ability to differentiate into a wide range of
pecialized cell types [55]. Drawbacks of using ES cells include their
ropensity to form teratomas when implanted in vivo due to their
luripotent state, and the cells are not autologous, thus limiting their
linical application due to problems with biological recognition and
ejection [49].
dult  stem  cells
dult stem cells are the best-understood cell type in stem cell
iology [56]. They could be retrieved from different adult tissues,
ncluding the brain, heart, lungs, kidney, and spleen [57]. The most
ell characterized source for adult stem cells is adult bone mar-
ow. Adult bone marrow contains a heterogeneous group of cells,
ncluding hematopoietic stem cells, macrophages, erythrocytes,
broblasts, adipocytes, and endothelial cells. In addition to these
ell types, non-hematopoietic stem cells exist possessing a multi-
ineage potential. These stem cells are commonly called marrow
tromal stem cells or mesenchymal stem cells, and more commonly
ow, mesenchymal stromal cells (MSCs). Originally, MSCs are
rimitive cells which derive from the mesoderm, being able to dif-
erentiate into connective tissues, skeletal muscle cells, and cells of
he vascular system [57]. Classifying MSCs as non-hematopoietic,
ultipotential stem cells make them capable of differentiating into
oth mesenchymal and non-mesenchymal cell lineages [57].
SCs home to and engraft to injured tissues. They synergistically
own-regulate pro-inflammatory cytokines and upregulate anti-
nflammatory factors thus modulating the inflammatory response.
oreover, MSCs demonstrate immunosuppressive properties via
uppressing T-cells, natural killer (NK) cell functions, and modu-
ating dentritic cell activities [57].
ultipotent bone marrow-derived MSCs are attractive candidates
or bladder tissue engineering as they can directly differentiate
nto smooth muscle cells. They could also act through a paracrine
ffect, as they are known to secrete a variety of pro-angiogenic, pro-
egenerative and mitogenic cytokines favoring tissue regeneration.
G
i
e
tW. Mahfouz et al.
t has been shown that human bone marrow MSCs can also differ-
ntiate into smooth muscle cells (SMCs) with the use of fetal bovine
erum (FBS) and TGF1 [58]. The regenerative potential of bone
arrow MSCs to replace tissue through their differentiation into
mooth muscle cells (SMCs) has been studied by several groups.
hukla et al. have cultured porcine MSCs and differentiated them
n vitro into mature SMCs. They showed that the labeled MSCs
urvived 2 weeks after implantation [46].
mniotic-fluid  and  placental-derived  stem  cells  (AFPS)
ultipotent amniotic-fluid and placental-derived stem (AFPS) cells
re capable of extensive self-renewal. They represent 1% of the
ells found in the amniotic fluid and placenta. The undifferentiated
tem cells expand extensively without a feeder cell layer and double
very 36 h. However, AFPS cells do not form tumors in vivo [49].
FPS cell lines can be induced to differentiate into cells from all
hree germ cell layers, including cells of adipogenic, osteogenic,
yogenic, endothelial, neural-like and hepatic lineages [59].
hese cells could be obtained either from amniocentesis or chori-
nic villous sampling in the developing fetus, or from the placenta
t the time of birth. De Coppi et al. were able to show that
uscle-differentiated AFPS cells prevented compensatory bladder
ypertrophy in a cryo-injured rodent bladder model [60]. AFPS
ells represent a new class of stem cells with properties somewhere
etween those of ES and adult stem cell types. They are more active
han adult stem cells, but less so than ES cells.
dipose-tissue  derived  stem  cells  (ADSCs)
dipose tissue is derived from mesoderm germ cell layer. It con-
ains a supportive connective tissue stroma of pluripotent progenitor
ells referred to as ADSCs. These stem cells have the ability to
ifferentiate into the three germ cell layers including, myogenic,
dipogenic, osteogenic, chrondrogenic, and neurogenic lineages in
itro. A major advantage in using ADSCs is that they are enormously
bundant and easily accessible [61], unlike other cell types used in
issue engineering. They can be easily obtained via liposuction pro-
edures using local anesthesia, and with minimal morbidity [62]. An
spirate of adipose tissue contains approximately 3% of ADSCs. In
omparison, the frequency of similar cells in bone marrow aspirates
s three times less [63].
he multipotentiality of ASCs, their ease of obtainment, and ability
o differentiate into functional and contractile smooth muscle make
hem an attractive source for bladder tissue engineering. In sev-
ral animal studies that are recently published or in press, ADSCs
ave demonstrated efficacy in the treatment of various types of
ysfunctional bladder and urethra [64,65].
rowth  factors
rowth factors initiate multiple effects involved in various aspects of
ell functioning, from reproduction and differentiation to apoptosis.
hey are sometimes called mitogens because they stimulate mitotic
ivision of the cell. Some of them are universal, whereas others are
pecific for certain cell types.rowth factors can accelerate the reproduction of MSCs and
nduce proliferation of resting clonogenic cells, which promotes
ither conservation of their undifferentiated phenotype or transi-
ion into the state of commitment. The same effects stimulate some
R[
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[
[
[
[
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[Bladder tissue engineering 
variants of their differentiation. Epidermal growth factor (EGF),
basic fibroblast growth factor (bFGF), and platelet-derived growth
factor (PDGF) belong to the factors studied enormously. Prolif-
eration and differentiation of MSCs are also influenced by some
other growth factors whose effects, however, are less significant
[66].
Clinical  trials  in  bladder  tissue  engineering
In the last decade several attempts to engineer urological tissue
have been reported. Furthermore, trials have been undertaken to
reconstruct even higher complex tissues, such as renal structures,
corpora cavernosa, and vaginal tissue. However, only few of these
approaches have advanced beyond animal experiments to human
clinical studies. The most noteworthy study to date on the clini-
cal applications of bladder substitutes is that of Atala et al. [1].
Patient-specific bladder tissue substitutes were created from autol-
ogous bladder tissue of seven patients with myelomeningocele who
required bladder augmentation. Patients first underwent open blad-
der biopsies 6 weeks prior to implantation for retrieval of smooth
muscle and urothelial cells. The two components were expanded in
vitro, seeded onto acellular collagen-based scaffolds, and then suc-
cessfully implanted into the respective patients. At a mean follow of
46 months, improvement in bladder capacity was evident. Histologic
analysis at 5-year follow up displayed tri-layered architecture com-
prised of urothelium, submucosa, and muscle. It is important to note
that these patients had end-stage bladder disease from myelodys-
plasia and they were dependent on intermittent catheterization to
achieve complete bladder emptying prior to surgery. Although evi-
dence of possible neural regeneration was seen in these tissue
constructs, the potential for postoperative volitional voiding remains
to be seen.
Conclusion
Bladder tissue engineering requires manipulation of different kinds
of cells, and various scaffold types, to share in the final outcome of
the engineered bladders, as regards the functionality and durability.
Bone marrow MSCs, Skeletal MSCs, ADSCs and AFPSCs have
been tested in preclinical trials for bladder augmentation and detru-
sor regeneration with various degrees of efficacy. Retrieval of stem
cells, especially bone marrow MSCs appears to be feasible, bypass-
ing the antigenic aspects and relatively inexpensive. Adipose tissue
is another source of abundant and easily obtained stem cells, how-
ever incorporation into more preclinical trials is paramount before
justifying their functionality, efficacy and durability. The use of
bladder acellular matrices is another alternative viable option when
considering scaffold use. However, prospective randomized trials
will dictate both the short-term and long-term outcomes of these
cells and scaffolds.
Despite these advances, challenges facing urology and other med-
ical disciplines are numerous. In regard to ES cells, ethical and
tumorigenicity concerns are paramount. As regard to adult stem
cells, their exact mechanism of action is still hypothetical; is it true
transdifferentiation leading to replenishment of degenerated tis-
sue? Or, do these stem cells secrete certain growth factors that
help the host tissue to regenerate? Answers to these questions
will direct future trials and will eventually widen the scope for
further use of tissue engineering in regenerative medicine as a
whole.
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Glossary  of  abbreviations
VEGF: vascular endothelial growth factor
TGF1: transforming growth factor 1
EGF: epidermal growth factor
TGF: transforming growth factor 
ECM: extracellular matrix
BSM: bladder submucosa
SIS: small intestinal submucosa
PGA: polyglycolic acid
PLA: polylactic acidPLGA: polylactic-co-glycolic acid
FDA: food and drug administration57
D: three dimensional
AGs: glycosaminoglycans
AM: bladder acellular matrix
S cells: embryonic stem cells
SCs: mesenchymal stromal cells
K cells: natural killer cells
MCs: smooth muscle cells
BS: fetal bovine serum
FPS: amniotic fluid and placental derived stem cells
DSCs: adipose-tissue derived stem cells
